Volume 31, Issue 3 (June 2020)
Studies in Medical Sciences 2020, 31(3): 188-198 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
hajabbas farshchi A, afzal ahangaran N, valikhani A, ghorbani S. THE EFFECT OF 2-CHLOROPYRIMIDINE ON K562 CELL LINE. Studies in Medical Sciences 2020; 31 (3) :188-198
URL: http://umj.umsu.ac.ir/article-1-3630-en.html
URL: http://umj.umsu.ac.ir/article-1-3630-en.html
MS of Immunology, Urmia University, Urmia, Iran (Corresponding Author) , alirezafarshchi67@yahoo.com
Abstract: (3029 Views)
Background & Aims: Previous studies indicated that pyrimidine derivatives possess anti-cancer properties. This study was set out to evaluate the effect of 2-chloropyrimidine as a pyrimidine derivative on K562 human erythroleukemia cell line and peripheral blood mononuclear cells (PBMCs) as normal control cells.
Materials & Methods: The K562 cells or PBMCs (1×106 cells/100 μl/well) were incubated for different time periods (24, 48, and 72 h) with a serial logarithmic dilution of analogue (1.5625-200µg/ml). After the incubation period, the survivability of cells was determined by MTT methods. After determining IC50 value, apoptosis and necrosis of cells were measured by PI/AO staining.
Results: Our data indicated that this compound had a profound cytotoxic effect on the K562 cell line in a dose-dependent manner so that the apoptosis increased and the survival test (MTT) decreased. Interestingly, the IC50 value of this compound against K562 was lower than IC50 value of this compound against PBMCs.
Conclusion: As a result, this compound provides more favorable cytotoxicity against K562 cell line without any additive cytotoxicity against PBMCs.
Materials & Methods: The K562 cells or PBMCs (1×106 cells/100 μl/well) were incubated for different time periods (24, 48, and 72 h) with a serial logarithmic dilution of analogue (1.5625-200µg/ml). After the incubation period, the survivability of cells was determined by MTT methods. After determining IC50 value, apoptosis and necrosis of cells were measured by PI/AO staining.
Results: Our data indicated that this compound had a profound cytotoxic effect on the K562 cell line in a dose-dependent manner so that the apoptosis increased and the survival test (MTT) decreased. Interestingly, the IC50 value of this compound against K562 was lower than IC50 value of this compound against PBMCs.
Conclusion: As a result, this compound provides more favorable cytotoxicity against K562 cell line without any additive cytotoxicity against PBMCs.
Type of Study: Clinical trials |
Subject:
پاتولوژی
References
1. Kawashima D, Asai M, Katagiri K, Takeuchi R, Ohtsuka K. Reinvestigation of the effect of carbenoxolone on the induction of heat shock proteins. Cell Stress Chaperones.2009 Sep 1;14(5):535-43. [DOI:10.1007/s12192-009-0106-0] [PMID] [PMCID]
2. Al-Issa SA. Synthesis and anticancer activity of some fused pyrimidines and related heterocycles. Saudi Pharm. J. 2013 Jul 31;21(3):305-16. [DOI:10.1016/j.jsps.2012.09.002] [PMID] [PMCID]
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000 Nov 15;96(10):3343-56.12-Coligan, J.E.; Bierer, B.E.; Margulies, D.H.; Shevach, E.M. and Strober, W., (2010.). Preface.Curr. Protoc. Immunol. [DOI:10.1182/blood.V96.10.3343.h8003343_3343_3356] [PMID]
4. Klein E, Vánky F, BenBassat H, Neumann H, Ralph P, Zeuthen J, Polliack A. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int. J. Cancer.1976 Oct 15;18(4):421-31. [DOI:10.1002/ijc.2910180405] [PMID]
5. Moosavi MA, Yazdanparast R, Sanati MH. The cytotoxic and anti-proliferative effects of 3-hydrogenkwadaphnin in K562 and jurkat cells is reduced by guanosine. BMB Rep. 2005;38(4):391-8. [DOI:10.5483/BMBRep.2005.38.4.391] [PMID]
6. Oslakovic C. The regulation of blood coagulation by high-density lipoprotein particles. Lund University; 2010. [URL]
7. Andreasen CB, Latimer KS. Separation of avian heterophils from blood using Ficoll-Hypaque discontinuous gradients. Avi. Dis. 1989 Jan 1:163-7. [DOI:10.2307/1591082] [PMID]
8. Sahi S, Tewatia P, Ghosal S. Leishmania donovani pteridine reductase 1: comparative protein modeling and protein-ligand interaction studies of the leishmanicidal constituents isolated from the fruits of Piper longum. J. Mol. Model. 2012 Dec 1;18(12):5065-73. [DOI:10.1007/s00894-012-1508-y] [PMID]
9. Korgaonkar KS, Ranade SS. Evaluation of acridine orange fluorescence test in viability studies on Escherichia coli. Can. J. Microbiol. 1966 Feb 1;12(1):185-90. [DOI:10.1139/m66-024] [PMID]
10. Bank HL. Rapid assessment of islet viability with acridine orange and propidium iodide. In vitro. Cell. Dev. Biol. 1988 Apr 1;24(4):266-73. [DOI:10.1007/BF02628826] [PMID]
11. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods. 1986 May 22;89(2):271-7. [DOI:10.1016/0022-1759(86)90368-6] [PMID]
12. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido [2, 3-d] pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000 Jun 15;60(12):3127-31. [Google Scholar]
13. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988 Feb 1;48(3):589-601 [Google Scholar]
14. Grzywacz B, Miller JS, Verneris MR. Use of natural killer cells as immunotherapy for leukaemia. Best Pract. Res, Clin. Haematol. 2008 Sep 30;21(3):467-83. [DOI:10.1016/j.beha.2008.07.008] [PMID] [PMCID]
15. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta, Gene Struct. Expression 1998 Oct 1;1400(1):173-84. [DOI:10.1016/S0167-4781(98)00134-1]
16. Shiraki N, Hamada A, Ohmura T, TOKUNAGA J, OYAMA N, NAKANO M. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biol.Pharm. Bull. 2001;24(5):555-7. [DOI:10.1248/bpb.24.555] [PMID]
17. Iwasaki K, MacKenzie EL, Hailemariam K, Sakamoto K, Tsuji Y. Hemin-mediated regulation of an antioxidant-responsive element of the human ferritin H gene and role of Ref-1 during erythroid differentiation of K562 cells. Mol. Cell. Biol. 2006 Apr 1;26(7):2845-56. [DOI:10.1128/MCB.26.7.2845-2856.2006] [PMID] [PMCID]
18. Koiso Y, Nakajima O, Matsumura D, Fujimoto Y, Hashimoto Y. [Chemical control of cell differentiation of human myeloleukemia K562 cell line]. Yakugaku zasshi. J. Pharm. Soc . Jpn. 2000 Jan;120(1):104-12. [DOI:10.1248/yakushi1947.120.1_104] [PMID]
19. Sutherland JA, Turner RA, Mannoni P, McGann LE, Turc JM. Differentiation of K562 leukemia cells along erythroid, macrophage, and megakaryocyte lineages. Int. J. Immunol. Immunother.1986 Jun 1;5(3):250-62. [Google Scholar]
20. Samad NA, Abdul AB, Abdullah R, Ibrahim TA, Rahman H, Keong YS. ZERUMBONE (ZER) INDUCES APOPTOSIS IN HEPG2 CELLS VIA MITOCHONDRIAL PATHWAY. Int. J. Pharm. Pharm. Sci.2015 Apr 3;7(5):298-302. [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
